Four of last week’s six initial public offering (IPO) candidates successfully launched into the public equity markets, but the reception was decidedly cool. The best performer was a biotech firm that had changed its focus and cut its IPO in half.

In the week ahead there are 14 companies planning to begin trading in the public markets, including 10 biotechs, a natural gas midstream company, a financial services firm, a restaurant chain, and a REIT.

IPO ETF manager Renaissance Capital reported that 49 IPOs have priced in the U.S. so far this year, down 50% from a year ago. Total proceeds raised through May 1st equaled $8 billion, down 58% compared with the same period in 2014. Of the 49 IPOs that have gone off this year, 22 have come from the healthcare sector. Last year’s IPO total came in at $85.2 billion, the highest total in the past ten years. Renaissance Capital does not include “best efforts” or blank check companies in its totals.

Here are the 14 IPOs scheduled for the week beginning May 4th.

OpGen Inc. is an early commercial stage healthcare company using molecular testing and bioinformatics to combat multi-drug resistant bacterial infections and is one of the two companies that delayed its IPO from last week. The company plans to offer 2.9 million units in an expected price range of $5.50 to $6.50 to raise $17 million on a market cap of around $64 million. Each unit comprises one share of common stock and one Offered Warrant to purchase one share of common stock at 110% of the IPO price. Sole bookrunner for the offering is Maxim Group LLC and the co-manager is National Securities. Units are expected to price on Monday and begin trading Tuesday on the Nasdaq under the ticker symbol OPGNW and shares will trade under the symbol OPGN.

CoLucid Pharmaceuticals Inc. is a Phase 3 clinical stage biopharmaceutical company developing a small-molecule acute treatment for migraine headaches and is the other IPO that was delayed from last week. The company plans to offer 5.4 million shares in an expected price range of $13 to $15 to raise $75 million on a market cap of $210 million. Joint bookrunners for the offering are Piper Jaffray and Stifel. Co-managers are William Blair and Ladenburg Thalmann & Co. No date has been stated for when the shares are expected to price or begin trading. Shares will be listed on the Nasdaq under the ticker symbol CLCD.

Gelesis Inc. is biotech firm products to induce weight loss and improve glycemic control in overweight and obese patients, including pre-diabetes and type 2 diabetes patients. The company plans to offer 4 million shares in an expected price range of $12 to $14 at a market cap of around $179 million. Joint bookrunners for the offering are Piper Jaffray, Stifel, and Guggenheim Securities. Shares are scheduled to price on Tuesday and to begin trading Wednesday on the Nasdaq under the ticker symbol GLSS.

MultiVir Inc. is a clinical-stage gene therapy company developing a pipeline of products for the treatment of multiple oncological indications. The company plans to offer 4.6 million shares in an expected price range of $12 to $14, raising about $60 million at a market cap of $193 million. Sole bookrunner for the offering is RBC Capital Markets, and co-managers include Nomura Securities, Cantor Fitzgerald, and LifeSci Capital. Shares are set to price on Tuesday and to begin trading Wednesday on the Nasdaq under the ticker symbol MVIR.

Adaptimmune Therapeutics plc is a U.K.-based clinical-stage biopharmaceutical company focused on novel cancer immunotherapy products. The company plans to offer 9.4 million American Depositary Shares (ADS) in an IPO price range of $15 to $16. Each ADS comprises 6 ordinary shares. The company plans to raise $150 million at a market cap of $1.1 billion. Joint bookrunners for the offering are BofA/Merrill Lynch, Cowen & Co., and Leerink Partners. Co-manager is Guggenheim Securities. The ADSes are scheduled to price on Wednesday and to begin trading Thursday on the Nasdaq under the ticker symbol ADAP.

aTyr Pharma Inc. is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using a set of physiological modulators known as physiocrines. The company plans to offer 5.4 million shares in an expected price range of $13 to $15 to raise $75 million at a market cap of about $316 million. Joint bookrunners for the offering are J.P. Morgan and Citi. Co-managers are BMO Capital Markets and William Blair. Shares are expected to price on Wednesday and to begin trading Thursday on the Nasdaq under the ticker symbol LIFE.

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products. The company plans to offer 5.8 million shares in an IPO price range of $12 to $14 to raise about $75 million with a market cap of $256 million. Joint bookrunners for the offering are Jefferies & Co. and Piper Jaffray. Co-managers are Wells Fargo Securities and Needham & Co. Shares are scheduled to price on Wednesday and to begin trading Thursday on the Nasdaq under the ticker symbol COLL.

ALSO READ: 10 Most Valuable Comic Book Movie Franchises

Commercial Credit Inc. is an independent financial services company engaged in the financing of commercial equipment. The company plans to offer 7.3 million shares in an expected price range of $15 to $17, raising $116 million at a market cap of $278 million. Joint bookrunners for the offering are J.P. Morgan and Keefe Bruyette Woods. Co-managers include BMO Capital Markets, Suntrust Robinson Humphrey, Wells Fargo Securities, and BB&T Capital Markets. Shares are scheduled to price on Wednesday and to begin trading Thursday on the New York Stock Exchange under the ticker symbol CCR.

HTG Molecular Design Inc. is a commercial stage company that developed and markets a novel technology platform to facilitate the routine use of complex molecular profiling. The company plans to offer 3.6 million shares in an IPO price range of $13 to $15 to raise $50 million at a market cap of around $94 million. Sole bookrunner for the offering is Leerink Partners. Co-managers are Canaccord Genuity and JMP Securities. Shares are scheduled to price on Wednesday and to begin trading Thursday on the NASDAQ under the ticker symbol HTGM.

Klox Technologies Inc. is a Canadian specialty pharmaceutical company focused on developing and commercializing products based on its proprietary BioPhotonic technology platform to address skin and soft tissue disorders. The company plans to offer 4.8 million shares in an expected price range of $13 to $15, raising $67 million at a market cap of about $353 million. Sole bookrunner for the offering is UBS Investment Bank. Co-managers are Canaccord Genuity, Needham & Co., and National Bank Financial. Shares are scheduled to price on Wednesday and to begin trading Thursday on the NASDAQ under the ticker symbol KLOX.

Tallgrass Energy GP LP is midstream natural gas corporation that will own about 22.5% of the membership interests in Tallgrass Equity LLC which, in turn, owns the incentive distribution rights and 1.37% of the general partner interest in Tallgrass Energy Partners LP (NYSE: TEP). The company will use proceeds from the IPO to acquire 20 million TEP common units, representing a 32.75% limited partner interest in TEP. The company plans to offer 35.3 million shares in an expected price range of $24 to $27, raising $900 million at a market cap of about $4 billion. Joint bookrunners for the offering include Citi, Goldman Sachs, BofA/Merrill Lynch, Barclays, Credit Suisse, Deutsche Bank, Morgan Stanley, RBC Capital Markets, and Wells Fargo Securities. Co-managers include Baird, Scotiabank/Howard Weil, Stifel, Tudor Pickering Holt & Co., and U.S. Capital Advisors. Shares are scheduled to price on Wednesday and to begin trading Thursday on the New York Stock Exchange under the ticker symbol TEGP.

Anterios Inc. is a clinical stage biopharmaceutical company focused on the development, manufacturing, and commercialization of novel botulinum products for therapeutic and aesthetic applications. The company plans to offer 3.9 million shares in an expected price range of $12 to $14 to raise about $51 million at a market cap of $175.5 million. Joint bookrunners are Stifel and RBC Capital Markets. Co-managers are JMP Securities and Needham & Co. Shares are scheduled to price on Thursday and to begin trading Friday on the Nasdaq under the ticker symbol ANTE.

Bojangles’ Inc. is a restaurant chain featuring Southern cooking that operated 254 company-owned stores and 368 franchised locations in 2014. The company plans to offer 6.3 million shares in an expected price range of $15 to $17, raising $100 million at a market cap of about $575 million. Joint bookrunners for the offering include BofA/Merrill Lynch, Wells Fargo Securities, Jefferies & Co., Barclays, Goldman Sachs, Piper Jaffray, William Blair, KeyBanc Capital Markets, and RBC Capital Markets. Co-managers are Stephens Inc. and Suntrust Robinson Humphrey. Shares are scheduled to price on Thursday and to begin trading Friday on the Nasdaq under the ticker symbol BOJA.

International Market Centers Inc. is a REIT that is the largest owner and operator of permanent business-to-business showroom space in North America for the home furniture industry and one of the largest owners and operators of permanent business-to-business showroom space for the home décor and gift industries. The company plans to offer 11.5 million shares in an expected price range of $12 to $14 to raise about $150 million at a market cap of about $645 million. Joint bookrunners for the offering are Barclays, Credit Suisse, Wells Fargo Securities, Deutsche Bank, and J.P. Morgan. Co-managers are KeyBanc Capital Markets and Raymond James. Shares are scheduled to price on Thursday and to begin trading Friday on the New York Stock Exchange under the ticker symbol IMC.

ALSO READ: 15 Companies Losing the Most Money

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.